ArticleLeukemia2015
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease.
Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- 18F-FDG PET or PET/CT in detecting high-grade transformation of chronic lymphocytic leukaemia and indolent lymphomas: a systematic review and meta-analysis.The British journal of radiology · 2025Pooled it
- Genetic background of Richter transformation of atypical chronic lymphocytic leukemia to diffuse large B-cell lymphoma - a case study.Journal of applied genetics · 2026Article
- Article
- Article
- Association of [Diagnostics (Basel, Switzerland) · 2025Article
- Efficacy and safety of BTK inhibitors in Richter's transformation: a systematic review of clinical evidence.Frontiers in oncology · 2025Review
- Updates in the Management of Richter Transformation.Cancers · 2024Review
- The Diagnostic Performance of 2-[Cancers · 2024Review
- 2-[Medicina (Kaunas, Lithuania) · 2024Article
- [Clinical and molecular biological characterization of patients with accelerated chronic lymphocytic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Richter's Transformation.Current oncology reports · 2022Review
- Biology and Treatment of Richter Transformation.Frontiers in oncology · 2022Review
- Richter Syndrome.Current oncology reports · 2021Review
- Non-Hodgkin Lymphoma Metabolism.Advances in experimental medicine and biology · 2021Article
- [Clinical value of PET/CT in the diagnosis of Richter syndrome].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Article
- Article
- Multimodality imaging of indolent B cell lymphoma from diagnosis to transformation: what every radiologist should know.Insights into imaging · 2019Review
- Current trends in the management of Richter's syndrome.International journal of hematologic oncology · 2018Review
- Richter transformation in the era of novel agents.Hematology. American Society of Hematology. Education Program · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 10 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to evaluate the predictive value of positron emission tomography-computed tomography (PET/CT) in discriminating the presence of a Richter's syndrome (RS) or a second malignancy (SM), as well as to evaluate its prognostic value in patients with chronic lymphocytic leukemia (CLL), we retrospectively analyzed the data of 90 patients who, in the suspicion of a RS or a SM, underwent PET/CT followed by the biopsy of the involved tissue. The median maximum Standardized Uptake Value (SUV max) in the presence of a CLL/small lymphocytic lymphoma, a diffuse large B-cell lymphoma (DLBCL), a Hodgkin lymphoma (HL), a SM were 3.5, 14.6, 7.0 and 6.3, respectively (P ⩽ 0.0001). A SUV max cutoff value ⩾ 5 showed a sensitivity, specificity, positive and negative predictive values of 88.2, 71.2, 51.3 and 94%, respectively, for the presence of a more aggressive disease (DLBCL, HL and SM). A SUV max ⩾ 5 identified also a subset of treatment naive patients with an inferior progression-free survival (P = 0.011) and overall survival (P = 0.067). These findings suggest that PET/CT may helpfully integrate the biologically-based prognostic stratification of CLL. Prospective clinical trials including larger cohorts of patients are needed to conclusively define the role and prognostic impact of PET/CT in the routine management of CLL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.